Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers.
about
Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitroAnti-Toxoplasma gondii activities and structure-activity relationships of novel fluoroquinolones related to trovafloxacinActivity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosisTrovafloxacin is active against Toxoplasma gondiiEfficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis.Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model.Effect of trovafloxacin on production of cytokines by human monocytes.Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography.Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters.Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.Oral bioavailability and pharmacokinetics of trovafloxacin in patients with AIDS.Pharmacokinetics of a fluoronaphthyridone, trovafloxacin (CP 99,219), in infants and children following administration of a single intravenous dose of alatrofloxacin.Successful trovafloxacin prophylaxis against experimental streptococcal aortic valve endocarditis.In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli.Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumoniaPharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeysComparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes.Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin.The new fluoroquinolones: A critical reviewEstimating xenobiotic half-lives in humans from rat data: influence of log P.Trovafloxacin: a new fluoroquinolone.Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model.Activity of trovafloxacin (with or without ampicillin-sulbactam) against enterococci in an in vitro dynamic model of infection.Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept.Postantibiotic effect of trovafloxacin against gram-positive and -negative organisms.A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilitiesAntistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones.Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha.
P2860
Q24673222-4F030873-560F-4949-A473-DC706D95ECD4Q28343422-7C523E23-9564-4D47-8D60-645A088A4DA3Q28378877-50785DCF-56D5-4457-BDA8-685CA52943F8Q28379193-7B807BC9-AA5D-44F2-89DC-F59A577F90BFQ33689451-8AD4BB53-3E96-4ED3-B90D-7C69188DB460Q33692694-97227B57-8BD9-49A5-9C8A-4F79CD833BA0Q33694154-010C1A60-5B15-48CF-B67A-B6ABB26A1A0EQ33695030-0ACA39DB-E757-4073-B4C6-D97FD89D5FC4Q33895157-F8E5DC3E-5EE7-4621-9918-EEECA3955622Q33976236-4C060425-8675-4316-A61C-F831982B6D17Q33978338-CB2E0D0E-56A7-40A6-B721-2611AE7A97B8Q33979388-6A8983C1-6D48-4923-89B1-FBF12F79E905Q33980637-6098B4C0-367F-445C-83E1-DDFAA04483ECQ33982034-026A5E87-13C0-4255-994C-347644DD0E87Q34734070-C029C32D-7F80-4D8D-8D89-4456FE084DF3Q35122254-B4B61208-07A2-4E48-B319-9C0C0124958AQ35122822-C64626E0-A09A-4012-B6A4-7405ABB02661Q35133082-EE5854C9-6806-4995-B2FA-1EC624165470Q35136607-0E57DCE7-A453-4D76-8C9F-8F801EA928F3Q35649595-90ACA175-CF8A-4D1D-B6A8-00B0986CD831Q36891261-3E3489D5-B5E4-49EF-A001-71A3840EE1D7Q37879173-519B7817-73B2-4497-9F5C-4E83398A4614Q39470200-650DE58D-0268-4CEA-9C2B-80398D8A6D24Q39556938-108A8F3E-A347-41E5-8354-4CBCB2B44882Q39557221-04C6D944-8515-4ADF-97D3-B800493E5541Q39557796-D0155189-0061-4D92-9FFD-9D0DA3CAA02FQ39559370-81BEFDAE-7C66-4BF6-B14B-6852D9281930Q42588154-A8A2BAD7-3823-4FD6-B8BC-01ABF5A63CA0Q54435973-A829BD7B-3636-4851-8320-9C7E1748B6F0
P2860
Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers.
description
1995 nî lūn-bûn
@nan
1995 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Pharmacokinetics and safety of ...... es to healthy male volunteers.
@ast
Pharmacokinetics and safety of ...... es to healthy male volunteers.
@en
Pharmacokinetics and safety of ...... es to healthy male volunteers.
@nl
type
label
Pharmacokinetics and safety of ...... es to healthy male volunteers.
@ast
Pharmacokinetics and safety of ...... es to healthy male volunteers.
@en
Pharmacokinetics and safety of ...... es to healthy male volunteers.
@nl
prefLabel
Pharmacokinetics and safety of ...... es to healthy male volunteers.
@ast
Pharmacokinetics and safety of ...... es to healthy male volunteers.
@en
Pharmacokinetics and safety of ...... es to healthy male volunteers.
@nl
P2093
P356
P1476
Pharmacokinetics and safety of ...... es to healthy male volunteers.
@en
P2093
P304
P356
10.1093/JAC/36.2.385
P407
P577
1995-08-01T00:00:00Z